|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Hyperplasia, benign prostatic |
|
Hypertension, essential |
| |
|
|
SIDE EFFECTS:
|
|
Dizziness |
|
vertigo |
|
Arrhythmias |
|
dyspnea |
|
orthostatic hypotension |
|
palpitations |
|
peripheral edema |
|
tachycardia |
|
Priapism |
|
Headache |
|
unusual tiredness |
|
Nausea |
|
nervousness, restlessness, or unusual irritability |
|
rhinitis |
|
somnolence |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Hepatic function impairment |
|
Renal function impairment |
|
|
ADULT DOSE:
|
|
Antihypertensive-
Initial: Oral, 1 mg (base) once a day.
Maintenance: Oral, the dosage being increased gradually to meet individual requirements; depending on periodic blood pressure measurements, dosage may be increased every two weeks, titrating upwards to 2, 4, 8, and 16 mg (base) once a day as needed and tolerated.
Note: Increases in dose beyond 4 mg (base) increase the likelihood of excessive postural effects including syncope, postural dizziness or vertigo, and postural hypotension.
Geriatric patients may be more sensitive to the effects of the usual adult dose.
Benign prostatic hyperplasia-
Initial: Oral, 1 mg (base) once a day, in the morning or in the evening.
Maintenance: Oral, 1 to 8 mg (base) once a day. Dosage increases made to 2 mg and afterwards to 4 mg and 8 mg once daily should be titrated at one- to two-week intervals. |
|
MAXIMUM ADULT DOSE:
|
|
16 mg once a day for hypertension.
8 mg once a day for BPH.
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established.
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|